Interleukin-6 inhibitors in non-COVID-19 ARDS: analyzing the past to step into the post-COVID-19 era

Gandini L, Fior G, Schibler A, Obonyo N.G, Li Bassi G, Suen JY, Fraser JF Critical Care DOI 10.1186/s13054-023-04394-w

Abstract: In March 2020, tocilizumab, an interleukin (IL)-6 inhibitor, was approved for the treatment of Coronavirus Disease 2019 acute respiratory distress syndrome by the Chinese National Health Commission. Since then, multiple IL-6 inhibitors, including sarilumab and siltuximab, have been used off-label against COVID-19, due to the lack of effective treatments and to slow down the high pandemic mortality.